Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Public Health Genomics ; 15(1): 1-10, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-21540562

RESUMO

BACKGROUND: Eighteen to twenty percent of breast cancer tumors show abnormal amplification of the Human Epidermal growth factor Receptor 2 (HER2) gene and increased expression of the associated protein. HER2 amplification is associated with rapid tumor proliferation and shorter disease-free and overall survival. Because women with HER2 amplification are more likely to benefit from treatment with the drug trastuzumab, testing for HER2 is recommended to guide therapy. However, little is known about use of HER2 testing in real-world settings. This study examined uptake, use, appropriateness of HER2 testing, and the relationship between HER2 test results and treatment decisions. METHODS: We assessed electronic data from 3,634 patients with invasive breast cancer diagnosed from 1998 to 2007 in a large integrated health system. We collected data on patient and tumor characteristics, HER2 testing status, test results, and trastuzumab treatment. RESULTS: From 1998 to 2000, the percent of patients who underwent HER2 evaluation increased from 12 to 94%; <3% of women with ductal carcinoma in situ, for whom HER2 testing is not recommended, were tested. Trastuzumab use increased 5-fold after 2004, when guidelines expanded to include recommending adjuvant treatment for early-stage breast cancer in addition to metastatic treatment. Ninety-five percent of women receiving trastuzumab had a positive HER2 result. After 2004, 55% of women with invasive breast cancer and overexpression of HER2 received trastuzumab treatment; this ranged from 44% of women with localized breast cancer to 80% of women with distant metastatic disease. CONCLUSIONS: These findings illustrate appropriate and effective implementation of a HER2 testing strategy in a managed care setting.


Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Neoplasias da Mama/genética , Carcinoma Intraductal não Infiltrante/genética , Tomada de Decisões , Testes Genéticos/estatística & dados numéricos , Receptor ErbB-2/genética , Receptor ErbB-2/metabolismo , Adulto , Idoso , Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/metabolismo , Carcinoma Intraductal não Infiltrante/tratamento farmacológico , Carcinoma Intraductal não Infiltrante/metabolismo , Estudos de Coortes , Feminino , Humanos , Técnicas Imunoenzimáticas , Hibridização in Situ Fluorescente , Invasividade Neoplásica , Programa de SEER , Trastuzumab
2.
J Am Osteopath Assoc ; 97(6): 347-52, 355, 1997 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9232945

RESUMO

The symptom of chest pain may be a result or manifestation of somatic dysfunction of the musculoskeletal system. Chest pain is a common chief complaint among patients in a family practice office or in the emergency room. Various intrathoracic and extrathoracic factors may be responsible. The authors describe their experience with one patient in whom osteopathic manipulative treatment was used along with accepted medical tests and therapy to diagnose and treat this patient. If chest pain is effectively diagnosed and promptly treated, OMT can provide the most thorough, cost-effective, and satisfying care available.


Assuntos
Dor no Peito/etiologia , Doenças Musculoesqueléticas/complicações , Dor no Peito/diagnóstico , Dor no Peito/terapia , Diagnóstico Diferencial , Humanos , Masculino , Manipulação Ortopédica , Pessoa de Meia-Idade , Doenças Musculoesqueléticas/diagnóstico , Doenças Musculoesqueléticas/terapia , Exame Físico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...